Trials / Completed
CompletedNCT00201864
Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
Phase II Trial of Exemestane (Aromasin) in Combination With Fulvestrant (Faslodex) in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Ohio State University Comprehensive Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to evaluate time to progression in women with hormone responsive advanced breast cancer treated with a combination of exemestane and fulvestrant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exemestane | 25 mg orally per day |
| DRUG | Fulvestrant | 250 mg IM starting on Day 8 and then every 28 days. |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2012-06-01
- Completion
- 2014-02-01
- First posted
- 2005-09-20
- Last updated
- 2018-07-26
- Results posted
- 2016-08-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00201864. Inclusion in this directory is not an endorsement.